App-Quantinova.ai

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Mirko Kroll - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

6-mercaptopurine

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Pre-Renal Transplant Education and Psychosocial Evaluation Positively Impacts Post-Transplant Medication Adherence

M. Jesse - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Prognostic Index of Circulating Tumor Cells for Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation

M. Chen - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

The “NAP-VAP” Study: Admission Computed Tomography of the Chest Detects Evidence of Occult Aspiration More Frequently than Chest Radiograph in Stroke Patients

Tasneem F. Hasan - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

LIVE BIRTH RATE IN INFERTILE PATIENTS WITH RECTOSIGMOID ENDOMETRIOSIS TREATED BY SURGERY OR IVF/ICSI

Simone Ferrero - American Society for Reproductive Medicine (ASRM) , 2021

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Endometriosis

N/A

Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

Rahul Aggarwal - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Pembrolizumab

A multi-physics approach enabling rare cell isolation with high recovery and high purity

Liping Yu - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prognosis and correlation with Ca19.9 of circulating tumor cells (CTCs) in locally advanced and metastatic pancreatic cancer.

Andrs J. Muoz Martn - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic pancreatic adenocarcinoma

N/A

Fetal membrane cells contribute to drug transportation across the maternal-fetal interface

Meagan V. Benson - Society for Maternal-Fetal Medicine (SMFM) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Rosuvastatin

Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study.

Qing Wei - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Apatinib

Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer.

Paolo D'Amico - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Breast cancer

N/A

Peripheral blood levels of tumor-infiltrating lymphocytes (TILs) and circulating tumor cells (CTCs) in patients with colorectal cancer.

Inna A. Novikova - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Schlafen 11 (SLFN11), a putative predictive biomarker of platinum/PARPi response, is frequently detected on circulating tumor cells (CTCs) in advanced prostate cancer.

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.

Jasmine Jiemei Wang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Relationship between circulating tumor cells and ZEB1 expression in tumor cells in colorectal cancer.

Inna A. Novikova - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mark Christopher Markowski - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).

Francesca Battaglin - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.

Nick Beije - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.

Jones T. Nauseef - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Filters

1671 Abstracts